| Zhai, Zhimin |
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) |
|
|
| Recruiting | 2 | 150 | RoW | AZD4205 | Dizal Pharmaceuticals | Peripheral T Cell Lymphoma | 05/25 | 12/26 | | |
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | 2 | 185 | RoW | HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor | Hutchison Medipharma Limited | Marginal Zone Lymphoma, Follicular Lymphoma | 04/24 | 12/24 | | |
NCT06642025: EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 9 | RoW | CAR-T Cell Injection | Zhimin Zhai, Zeno Therapeutics Pte. Ltd | Acute Myeloid Leukemia (AML), CAR-T | 08/26 | 09/29 | | |
EECNTL, NCT02735291: Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia |
|
|
| Active, not recruiting | N/A | 72 | RoW | CD19-targeted CAR-T cells | Sinobioway Cell Therapy Co., Ltd., The Second Hospital of Anhui Medical University | Leukemia | 12/19 | 12/25 | | |
